Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Amyotrophic Lateral Sclerosis | Review

Emerging roles and mechanisms of miR-206 in human disorders: a comprehensive review

Authors: Sheyda Khalilian, Seyedeh Zahra Hosseini Imani, Soudeh Ghafouri-Fard

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

As a member of the miR-1 family, miR-206 is located between IL-17 and PKHD1 genes in human. This miRNA has been shown to be involved in the pathogenic processes in a variety of human disorders including cancers, amyotrophic lateral sclerosis, Alzheimer’s disease, atherosclerosis, bronchopulmonary dysplasia, coronary artery disease, chronic obstructive pulmonary disease, epilepsy, nonalcoholic fatty liver disease, Hirschsprung disease, muscular dystrophies, pulmonary arterial hypertension, sepsis and ulcerative colitis. In the current review, we summarize the role of miR-206 in both malignant and non-malignant situations and explain its possible therapeutic implications.
Literature
1.
Jalali-Qomi S, Motovali-Bashi M, Rezaei H, Khalilian S. Experimental validation of a predicted microRNA within human FVIII gene. Molecular Biology Research Communications. 2021;10(2):45.
2.
Kadkhoda S, Ghafouri-Fard S. The importance of miRNA-630 in human diseases with an especial focus on cancers. Cancer Cell Int. 2022;22(1):105.CrossRef
3.
Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205.CrossRef
4.
Kadkhoda S, Ghafouri-Fard S. Function of miRNA-145–5p in the pathogenesis of human disorders. Pathol Res Pract. 2022;231:153780.CrossRef
5.
Ma G, Wang Y, Li Y, Cui L, Zhao Y, Zhao B, et al. MiR-206, a key modulator of skeletal muscle development and disease. Int J Biol Sci. 2015;11(3):345.CrossRef
6.
7.
8.
9.
Rezaei H, Motovali-Bashi M, Khalilian S. Identification of Novel miRNAs in the F8 Gene Via Bioinformatics Tools. Iranian Journal of Biotechnology. 2021;19(2):e2700.
10.
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Kadkhoda S, Taheri M, Tafrishinejad A. A review on the role of miR-149-5p in the carcinogenesis. Int J Mol Sci. 2021;23(1):415.CrossRef
11.
Ghafouri-Fard S, Shaterabadi D, Abak A, Shoorei H, Bahroudi Z, Taheri M, et al. An update on the role of miR-379 in human disorders. Biomed Pharmacother. 2021;139: 111553.CrossRef
12.
Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–62.CrossRef
13.
Cao H, Liu Z, Huang P, Yue Y, Xi J. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 2019;23(3):1012–21.
14.
Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W, et al. Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochem Biophys Res Commun. 2015;463(4):1115–21.CrossRef
15.
Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 2013;433(2):207–12.CrossRef
16.
Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. MiR-206 expression is down-regulated in estrogen receptor α–positive human breast cancer. Can Res. 2008;68(13):5004–8.CrossRef
17.
Samaeekia R, Adorno-Cruz V, Bockhorn J, Chang Y-F, Huang S, Prat A, et al. miR-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 Pathwaymir-206 inhibits stemness and metastasis. Clin Cancer Res. 2017;23(4):1091–103.CrossRef
18.
Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, et al. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget. 2016;7(17):24537.CrossRef
19.
Chen AH, Qin YE, Tang WF, Tao J, Song HM, Zuo M. MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer. Cancer Cell Int. 2017;17(1):1–9.CrossRef
20.
Hesari Z, Nourbakhsh M, Hosseinkhani S, Abdolvahabi Z, Alipour M, Tavakoli-Yaraki M, et al. Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells. Gene. 2018;673:149–58.CrossRef
21.
Adams BD, Cowee DM, White BA. The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-α (ERα) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol. 2009;23(8):1215–30.CrossRef
22.
Wang R, Zhang T, Yang Z, Jiang C, Seng J. Long non-coding RNA FTH 1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB 1. J Cell Mol Med. 2018;22(9):4068–75.CrossRef
23.
Zhou Y, Wang M, Tong Y, Liu X, Zhang L, Dong D, et al. miR-206 promotes cancer progression by targeting full-length neurokinin-1 receptor in breast cancer. Technol Cancer Res Treat. 2019;18:1533033819875168.CrossRef
24.
Sun Q, Qi X, Zhang W, Li X. Knockdown of circRNA_0007534 suppresses the tumorigenesis of cervical cancer via miR-206/GREM1 axis. Cancer Cell Int. 2021;21(1):1–14.CrossRef
25.
Wang Y, Tian Y. miR-206 inhibits cell proliferation, migration, and invasion by targeting BAG3 in human cervical cancer. Oncol Res. 2018;26(6):923.CrossRef
26.
Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem. 2009;284(46):31921–7.CrossRef
27.
Parasramka MA, Dashwood WM, Wang R, Saeed HH, Williams DE, Ho E, et al. A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis. Clin Epigenetics. 2012;4(1):1–10.CrossRef
28.
Meng X, Fu R. miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells. Onco Targets Ther. 2018;11:1757.CrossRef
29.
Zheng Y, Yang X, Wang C, Zhang S, Wang Z, Li M, et al. HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway. Sci Rep. 2020;10(1):1–12.
30.
Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma. Cancer Lett. 2012;314(1):41–53.CrossRef
31.
Dai C, Xie Y, Zhuang X, Yuan Z. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 2018;104:763–70.CrossRef
32.
Yu X, Zhang X, Wang G, Wang B, Ding Y, Zhao J, et al. miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer. Cancer Cell Int. 2020;20(1):1–16.CrossRef
33.
Zhang C, Luo Y, Cao J, Wang X, Miao Z, Shao G. Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR-206 to upregulate NETO2 and FOXP1 expression. Cancer Med. 2020;9(22):8600–11.CrossRef
34.
Wang S-H, Zhang W-J, Wu X-C, Zhang M-D, Weng M-Z, Zhou D, et al. Long non-coding RNA Malat1 promotes gallbladder cancer development by acting as a molecular sponge to regulate miR-206. Oncotarget. 2016;7(25):37857.CrossRef
35.
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen Z, et al. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 2013;332(1):94–101.CrossRef
36.
Pang C, Huang G, Luo K, Dong Y, He F, Du G, et al. miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med. 2017;6(10):2398–409.CrossRef
37.
Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31(11):3859–63.
38.
Yu W, Wang H, Lu B, Zhang G, Ma H, Wu Z. miR-206 inhibits human laryngeal squamous cell carcinoma cell growth by regulation of cyclinD2. Eur Rev Med Pharmacol Sci. 2015;19(14):2697–702.
39.
Wang X, Yu B, Jin Q, Zhang J, Yan B, Yang L, et al. Regulation of laryngeal squamous cell cancer progression by the lncRNA RP11-159K7. 2/miR-206/DNMT3A axis. J Cell Mol Med. 2020;24(12):6781–95.CrossRef
40.
Liu C, Li J, Wang W, Zhong X, Xu F, Lu J. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression. Cell Cycle. 2020;19(10):1077–88.CrossRef
41.
Chen QY, Jiao DM, Yan L, Wu YQ, Hu HZ, Song J, et al. Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis. Mol Biosyst. 2015;11(8):2290–302.CrossRef
42.
Jiao D, Chen J, Li Y, Tang X, Wang J, Xu W, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med. 2018;22(7):3526–36.CrossRef
43.
Wang T, Dong X-M, Zhang F-L, Zhang J-R. miR-206 enhances nasopharyngeal carcinoma radiosensitivity by targeting IGF1. Kaohsiung J Med Sci. 2017;33(9):427–32.CrossRef
44.
Wu K, Li J, Qi Y, Zhang C, Zhu D, Liu D, et al. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. Biomed Pharmacother. 2019;116: 108995.CrossRef
45.
Sheng N, Xu Y-Z, Xi Q-H, Jiang H-Y, Wang C-Y, Zhang Y, et al. Overexpression of KIF2A is suppressed by miR-206 and associated with poor prognosis in ovarian cancer. Cell Physiol Biochem. 2018;50(3):810–22.CrossRef
46.
Zhang Y, Guo J, Cai E, Cai J, Wen Y, Lu S, et al. HOTAIR maintains the stemness of ovarian cancer stem cells via the miR-206/TBX3 axis. Exp Cell Res. 2020;395(2): 112218.CrossRef
47.
Liu F, Yin R, Chen X, Chen W, Qian Y, Zhao Y, et al. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. Biomed Pharmacother. 2019;114: 108605.CrossRef
48.
Wang P, Guo L, Liang Z, Lou J, Zhao J. Baicalein inhibits cell development in papillary thyroid cancer by regulating miR-206/RAP1B pathway. Trop J Pharm Res. 2020;19(7):1383–8.CrossRef
49.
Ding T, Zhu Y, Jin H, Zhang P, Guo J, Zheng J. Circular RNA circ_0057558 controls prostate cancer cell proliferation through regulating miR-206/USP33/c-Myc Axis. Front Cell Dev Biol. 2021;9: 644397.CrossRef
50.
Wang Y, Xu H, Si L, Li Q, Zhu X, Yu T, et al. MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. Prostate. 2018;78(7):479–90.CrossRef
51.
Wei C, Wang S, Ye ZQ, Chen ZQ. miR-206 inhibits renal cell cancer growth by targeting GAK. J Huazhong Univ Sci Technol Med Sci. 2016;236(6):852–8.CrossRef
52.
Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018;10(1):1–9.CrossRef
53.
Miyachi M, Tsuchiya K, Yoshida H, Yagyu S, Kikuchi K, Misawa A, et al. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun. 2010;400(1):89–93.CrossRef
54.
Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H, et al. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum Genet. 2017;62(1):113–21.CrossRef
55.
Wang P, Gu J, Wang K, Shang J, Wang W. miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B. J Cell Biochem. 2019;120(11):18927–36.CrossRef
56.
Fu Y, Shao Z, He Q, Jiang B, Wu Y, Zhuang Z. Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43. Eur Rev Med Pharmacol Sci. 2015;19(11):2091–104.
57.
Li H, Xu W, Xia Z, Liu W, Pan G, Ding J, et al. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling. Aging. 2021;13(3):4522.CrossRef
58.
Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, et al. miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Mol Oncol. 2014;8(8):1690–702.CrossRef
59.
Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, et al. Serum miRNAs miR-206, 143–3p and 374b–5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 2017;55:123–31.CrossRef
60.
Xie B, Liu Z, Jiang L, Liu W, Song M, Zhang Q, et al. Increased serum miR-206 level predicts conversion from amnestic mild cognitive impairment to Alzheimer’s disease: a 5-year follow-up study. J Alzheimers Dis. 2017;55(2):509–20.CrossRef
61.
Moon J, Lee S-T, Kong IG, Byun J-I, Sunwoo J-S, Shin J-W, et al. Early diagnosis of Alzheimer’s disease from elevated olfactory mucosal miR-206 level. Sci Rep. 2016;6(1):1–9.CrossRef
62.
Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol. 2012;72(2):269–77.CrossRef
63.
Shao Y, Xu T. A study on the neuroprotective effect of miR-206–3p on Alzheimer’s disease mice by regulating brain-derived neurotrophic factor. Ann Transl Med. 2022;10(2):85.CrossRef
64.
Tian N, Cao Z, Zhang Y. MiR-206 decreases brain-derived neurotrophic factor levels in a transgenic mouse model of Alzheimer’s disease. Neurosci Bull. 2014;30(2):191–7.CrossRef
65.
Gao Y, Yue J, Huang Z. LncRNA MIAT mediates ox-LDL-induced endothelial cell injury via miR-206/RAB22A axis. J Surg Res. 2021;265:303–12.CrossRef
66.
Duan J, Zhang X, Zhang S, Hua S, Feng Z. miR-206 inhibits FN1 expression and proliferation and promotes apoptosis of rat type II alveolar epithelial cells. Exp Ther Med. 2017;13(6):3203–8.CrossRef
67.
Wang M, Ji Y, Cai S, Ding W. MiR-206 suppresses the progression of coronary artery disease by modulating vascular endothelial growth factor (VEGF) expression. Med Sci Monit. 2016;22:5011.CrossRef
68.
Tang Y, Zhang Y, Chen Y, Xiang Y, Xie Y. Role of the micro RNA, miR-206, and its target PIK 3C2α in endothelial progenitor cell function–potential link with coronary artery disease. FEBS J. 2015;282(19):3758–72.CrossRef
69.
Sun Y, An N, Li J, Xia J, Tian Y, Zhao P, et al. miRNA-206 regulates human pulmonary microvascular endothelial cell apoptosis via targeting in chronic obstructive pulmonary disease. J Cell Biochem. 2019;120(4):6223–36.CrossRef
70.
Liu N, Williams AH, Maxeiner JM, Bezprozvannaya S, Shelton JM, Richardson JA, et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Investig. 2012;122(6):2054–65.CrossRef
71.
Hu J, Kong M, Ye Y, Hong S, Cheng L, Jiang L. Serum miR-206 and other muscle-specific micro RNA s as non-invasive biomarkers for Duchenne muscular dystrophy. J Neurochem. 2014;129(5):877–83.CrossRef
72.
Wu Z, Liu Y, Huang J, Huang Y, Fan L. MiR-206 inhibits epilepsy and seizure-induced brain injury by targeting CCL2. Cytotechnology. 2019;71(4):809–18.CrossRef
73.
Zhang J, Fan J, Zeng X, Nie M, Luan J, Wang Y, et al. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B. 2021;11(3):609–20.CrossRef
74.
Sharan A, Zhu H, Xie H, Li H, Tang J, Tang W, et al. Down-regulation of miR-206 is associated with Hirschsprung disease and suppresses cell migration and proliferation in cell models. Sci Rep. 2015;5(1):1–7.CrossRef
75.
Luo J, Han J, Li Y, Liu Y. Downregulated SOX9 mediated by miR-206 promoted cell apoptosis in Legg-Calvé-Perthes disease. Oncol Lett. 2018;15(1):1319–24.
76.
Pegoraro V, Angelini C. Circulating miR-206 as a biomarker for patients affected by severe limb girdle muscle dystrophies. Genes. 2021;12(1):85.CrossRef
77.
Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda SI, et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014;19(6):452–8.CrossRef
78.
79.
Liang G, Wu Y, Guan Y, Dong Y, Jiang L, Mao G, et al. The correlations between the serum expression of miR-206 and the severity and prognosis of sepsis. Ann Palliat Med. 2020;9(5):3222–34.CrossRef
80.
Valsecchi V, Anzilotti S, Serani A, Laudati G, Brancaccio P, Guida N, et al. miR-206 reduces the severity of motor neuron degeneration in the facial nuclei of the brainstem in a mouse model of SMA. Mol Ther. 2020;28(4):1154–66.CrossRef
81.
Minacapelli CD, Bajpai M, Geng X, Van Gurp J, Poplin E, Amenta PS, et al. miR-206 as a biomarker for response to mesalamine treatment in ulcerative colitis. Inflamm Bowel Dis. 2019;25(1):78–84.CrossRef
Metadata
Title
Emerging roles and mechanisms of miR-206 in human disorders: a comprehensive review
Authors
Sheyda Khalilian
Seyedeh Zahra Hosseini Imani
Soudeh Ghafouri-Fard
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02833-2

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Primary research

ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway

Review

CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

Correction

Correction: Identifying the novel key genes in renal cell carcinoma by bioinformatics analysis and cell experiments

Primary research

LINC00665 up-regulates SIN3A expression to modulate the progression of colorectal cancer via sponging miR-138-5p

Primary research

miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling

Review

Induction and application of ferroptosis in cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits